# Task A02: Product Development Planning and Evaluation - The Lilly TB Drug Discovery Initiative

> **NIH NIH N02** · RESEARCH TRIANGLE INSTITUTE · 2022 · $25,389

## Abstract

The Non-clinical Services for Development of Interventional Agents for Infectious Diseases program provides services to facilitate preclinical product development of promising therapeutics for infectious disease-causing pathogens and/or toxins. Services include: preclinical product development planning and evaluation; lead identification and development; chemistry and GMP manufacturing; in vitro and in vivo preclinical microbiological, safety, toxicology and pharmacokinetics.

## Key facts

- **NIH application ID:** 10706296
- **Project number:** 272201800002I-P00004-759301900134-1
- **Recipient organization:** RESEARCH TRIANGLE INSTITUTE
- **Principal Investigator:** DIANA STEVENS
- **Activity code:** N02 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $25,389
- **Award type:** —
- **Project period:** 2019-08-31 → 2022-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10706296

## Citation

> US National Institutes of Health, RePORTER application 10706296, Task A02: Product Development Planning and Evaluation - The Lilly TB Drug Discovery Initiative (272201800002I-P00004-759301900134-1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10706296. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*